share_log

Canaccord Genuity Maintains Sell on Vertex Pharmaceuticals, Raises Price Target to $376

Benzinga ·  Jul 31 08:38  · Ratings

Canaccord Genuity analyst Whitney Ijem maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sell and raises the price target from $371 to $376.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment